

Supplementary Table 1. Baseline characteristics of patients with biopsy-proven NAFLD in the derivation cohort grouped by the severity of fibrosis (fibrosis stage F < 2 and fibrosis stage F ≥ 2)

	Fibrosis stage F < 2 (n = 84)	Fibrosis stage F ≥ 2 (n = 16)	<i>p</i>
Age (years)	40.83 ± 12.18	37.56 ± 15.08	0.346
Sex (men)	57 (67.86%)	12 (75.00%)	0.571
BMI (kg/m ²)	27.41 ± 4.47	29.14 ± 7.38	0.237
Waist circumference (cm)	93.45 ± 9.32	98.95 ± 20.09	0.692
AST (U/l)	45.87 ± 28.92	65.14 ± 47.61	0.044
ALT (U/l)	70.99 ± 48.73	91.79 ± 74.55	0.183
TC (mmol/l)	5.24 ± 1.31	4.70 ± 1.31	0.164
TG (mmol/l)	2.75 ± 1.62	2.29 ± 1.12	0.308
HDL-C (mmol/l)	0.99 ± 0.21	0.94 ± 0.15	0.389
LDL-C (mmol/l)	3.09 ± 0.96	2.78 ± 1.05	0.280
HbA1c (%)	6.25 ± 1.24	7.19 ± 2.01	0.022
Creatinine (mmol/l)	70.09 ± 15.22	68.14 ± 16.57	0.665
eGFR	113.82 ± 18.81	115.26 ± 17.73	0.792
Hypertension (%)	17 (20.24%)	4 (25.00%)	0.668
T2DM (%)	24 (28.57%)	7 (43.75%)	0.229
Obesity (%)	51 (60.71%)	11 (68.75%)	0.544
Steatosis			0.818
1	31 (36.90%)	6 (37.50%)	
2	27 (32.14%)	4 (25.00%)	
3	26 (30.95%)	6 (37.50%)	
Ballooning			0.763
0	14 (16.67%)	3 (18.75%)	
1	50 (59.52%)	8 (50.00%)	
2	20 (23.81%)	5 (31.25%)	
Lobular inflammation			0.031
0	2 (2.38%)	0 (0.00%)	
1	58 (69.05%)	7 (43.75%)	
2	24 (28.57%)	8 (50.00%)	
3	0 (0.00%)	1 (6.25%)	

Abbreviations: ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; eGFR, estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; TG: triglyceride; TC: total cholesterol.